A BSTRACT
It is believed that G-protein-coupled receptors are the most promising target proteins for drug research. The β 2 -adrenergic receptor has been analyzed extensively in terms of its structure, regulation and signaling as a prototype G-protein-coupled receptor. Recent development of a recombinant β 2 -adrenergic receptor reveals that the receptor exists in different conformations in addition to the resting and active forms. Furthermore, different conformations that are important for coupling with G-proteins are induced in a ligand-specific manner. After the receptor binds an agonist, the receptor is phosphorylated by G-proteincoupled receptor kinase or second messengerdependent kinase. β -Arrestin is a cytosolic protein that binds to receptors phosphorylated by G-proteincoupled receptor kinase, but not those phosphorylated by second messenger-dependent kinase, and plays important roles in agonist-induced desensitization. However, β -arrestin has recently been recognized as a scaffold protein that helps to achieve efficient transmission of internalization and signaling. Receptor agonists can be divided into two groups: full and partial agonists. Partial agonists have an advantage over full agonists because desensitization is less likely to be induced following stimulation with a partial agonist. However, the effects of partial agonists on β -arrestin-mediated signaling and internalization have not been fully examined so far. Information regarding the binding sites of partial agonists is still not sufficient to explain why they cannot fully activate the receptor. In the present study, recent progress regarding the structure, regulation and signaling of β 2 adrenergic receptors and about differences between full and partial agonists will be summarized.
Key words: β 2 -adrenergic receptor selective agonist, agonist-specific conformation, constitutively active receptor, full agonist, partial agonist, regulation, scaffold protein.
I NTRODUCTION
G-protein-coupled receptors (GPCR) are well known as drug targets. In fact, the targets of approximately 50% of drugs that are available commercially on the market are GPCR. 1 The β -adrenergic receptor is considered as a prototype GPCR and has been studied extensively. β -Adrenergic receptors are classified into three subtypes: β 1 , β 2 and β 3 . The β 1 -adrenergic receptor subtype is mainly involved in increasing heart rate and causing contraction of the heart, whereas stimulation of the β 2 -adrenergic receptor subtype relaxes smooth muscle. The β 3 -adrenergic receptor subtype is speculated to be a promising target for anti-obesity drugs. Drugs are defined by three properties: affinity, efficacy and duration of action. Each drug has its own intrinsic properties. Of the three drug properties, subtype selectivity is linked directly to affinity and is important for drug treatment, because serious side-effects can be avoided using drugs with higher receptor affinity. The binding site of β 2 -adrenergic receptors has been analyzed extensively among the GPCR and a model of the agonist-receptor complex has been proposed. In the present review, the current understanding of various aspects of β 2 -adrenergic receptors, such as agonist-induced conformational changes of the receptor, regulation, signaling and the relationship between polymorphism and drug response, will be summarized. In addition, differences between partial and full agonists will be discussed.
RECEPTORS
The GPCR exist on the cell surface and bind agonists to elicit cellular responses. Recent progress in receptor research reveals that a small number of of receptors exist in the active state even in the absence of an agonist and that receptors are in equilibrium between the resting and active states ( Fig. 1 ). 2 Drugs acting on receptors are classified into two groups: agonists and antagonists. Antagonists are further divided into neutral antagonists and inverse agonists. Neutral antagonists bind to receptors in the resting or active state, but do not change the equilibrium between the two states. In contrast with neutral antagonists, inverse agonists shift the equilibrium towards the inactive state. Agonists are divided into partial and full agonists. Full agonists are defined as agonists that maximally activates the receptor, whereas partial agonists are defined as agonists that cannot fully activate the receptor even though all receptors are occupied by the agonist. Agonists should bind to critical amino acids for activation of G-proteins. It has been demonstrated that aspartic acid at position 113 (Asp 113 ) of the human β 2 -adrenergic receptor binds to the amino group of the full agonist isoproterenol and that Ser 204 and Ser 207 interact with the catechol hydroxyl group at the meta or para positions of isoproterenol, respectively ( Fig. 2 ). 3 Based on these results, it is reasonable to assume that a full agonist is converted to a partial agonist when the interaction between the receptor and full agonist is disrupted by steric hindrance of the receptor or chemical modification of the agonist. In addition to Ser 204 and Ser 207 , we have demonstrated previously that another Ser (Ser 203 ) next to Ser 204 is also involved in the interaction with the hydroxyl group of catechol at the para position. 4 Our finding was later confirmed by Liapakis et al . 5 Asparagine at position 293 (Asn 293 ) has been proposed to interact with the hydroxyl group at the β position that determines the stereospecific interaction of an agonist with the receptor. 6 However, isoproterenol does not show subtype selectivity for β 1 -and β 2 -adrenergic receptors. Thus, we determined the binding site on the β 2 -adrenergic receptor conferring subtype-selective, high-affinity binding. [7] [8] [9] We also determined the structural requirements for an agonist to be subtype selective for the β 2 -adrenergic receptor.
B INDING SITE FOR β 2 -ADRENERGIC RECEPTOR -SELECTIVE AGONISTS
There are many agonists that show β 2 -adrenergic receptor selectivity, such as salmeterol, procaterol and formoterol. Among the β 2 -adrenergic receptor-selective agonists, we first used TA-2005 to determine β 2 -adrenergic receptor subtype-selective binding sites, because derivatives of TA-2005 are available for analysis. 7 It has been reported that TA-2005 has a long duration of action in addition to β 2 -adrenergic receptor selectivity. 10 TA-2005 has structural features that include saligenin and methoxyphenyl groups. Among the derivatives of TA-2005, the compound that lacks the methoxyphenyl group lost β 2 -adrenergic receptor selectivity and the affinity of this compound for β 2 -adrenergic receptors was essentially the same as for β 1 -adrenergic receptors. 7 This demonstrates the importance of the methoxyphenyl group of TA-2005 for β 2 -adrenergic receptor selectivity. Structural analysis of subtype-selective agonists has revealed an interesting structure that is often attached to the amino group of the agonist, 7 consistent with our results. Our results also indicate that β 2 -adrenergic receptors have region(s) or amino acid(s) that are responsible for binding of the methoxyphenyl group of TA-2005. By constructing various chimeric β 1 -and β 2 -adrenergic receptors, we have identified the seventh transmembrane domain (TM7) as the most important domain for β 2 -adrenergic receptor-selective, high-affinity binding. 7 Then, the 10 amino acids in TM7 that are different to that of the β 1 -adrenergic receptor were individually mutated to Ala. The resulting Ala-substituted mutants demonstrated that mutation of Tyr 308 , but not other amino acids, decreased the affinity of the receptor for TA-2005. These results indicate that Tyr 308 is a major determinant for high-affinity binding of β 2 -adrenergic receptor-selective agonists. The model of the β 2 -adrenergic receptor-TA-2005 complex is shown in Fig. 3 . Subsequent experiments from our group demonstrated that Tyr 308 is important for β 2 -adrenergic receptor-selective, high-affinity binding not only of TA-2005, but also of other β 2 -adrenergic receptor-selective agonists such as salmeterol, procaterol and formoterol. 8, 9 BINDING TO A CONSTITUTIVELY ACTIVE RECEPTOR When a mutation is introduced at a specific location in the β 2 -adrenergic receptor, the receptor assumes to transform into an active conformation even in the absence an agonist. 11 This is referred to as a constitutively active receptor. When the amino acids Leu 266 , Lys 267 , His 269 and Leu 272 at the end of the intracellular third loop were mutated to Ser, Arg, Lys and Ala locating, the resultant β 2 -adrenergic receptor became a constitutively active receptor, because it could stimulate adenylyl cyclase without the presence of an agonist and showed a highaffinity state for agonists. 11 Although neutral antagonists did not decrease basal adenylyl cylase activity of the mutant receptor, inverse agonists decreased its activity. Therefore, it is concluded that the mutation transforms the receptor into an active form.
It is believed that the β 2 -adrenoceptor has at least two different conformations: resting and active. However, it is not certain whether the mutation-induced active conformation of the β 2 -adrenergic receptor is the same conformation as that induced by agonist binding. When agonist-binding characteristics were examined in constitutively active β 2 -adrenergic receptors, 11 all agonists had increased affinity for the constitutively active receptor. It is interesting that the increased affinity of an agonist for the receptor depends on its efficacy. Because the receptor in an active conformation has a higher affinity for agonists than receptors in the resting state, mutation really creates an active receptor. The degree of the increase in the affinity of partial agonists is lower than that of full agonists. To examine conformational changes occurring in the binding sites of β 2 -adrenergic receptor-selective agonists upon activation, substitution of Ser 204 or Ser 207 with Ala was introduced into the constitutively active mutant β 2 -adrenergic receptor. 12 When the binding characteristics of the Ala-substituted constitutively active mutant receptor were compared with those of the constitutively active mutant, the following binding characteristics were found. In the resting state, salmeterol, salbutamol and TA-2005 interact more strongly with Ser 204 of the β 2 -adrenergic receptor than Ser 207 . In contrast with the resting state of the receptor, these three β 2 -adrenergic receptor-selective agonists interact equally with Ser 204 and Ser 207 in the active state. However, isoproterenol interacts equally with Ser 204 and Ser 207 in both the resting and active states. Thus, salmeterol, salbutamol and TA-2005, but not isoproterenol, interact equally with Ser 204 and Ser 207 of the receptor in the active conformation. These results indicate that the interaction between the saligenin group of the agonist and the two Ser residues is different for β 2 -adrenergic receptors in the resting state compared with the active state.
INVOLVEMENT OF DIFFERENT AMINO ACIDS IN THE BINDING OF AGONISTS AND ANTAGONISTS
The binding site for β 2 -adrenergic receptor subtypeselective antagonists has been determined by constructing chimeric β 1 -and β 2 -adrenergic receptors. Marullo et al. demonstrated that high-affinity binding for β 2adrenergic receptor-selective antagonists was not determined by a single transmembrane domain, but that it is determined by more than two transmembrane domains in a concerted manner. 13 However, it would be difficult to confirm the involvement of a single transmembrane domain in the high-affinity binding of β 2 -adrenergic receptor subtype-selective antagonists, because these compounds interacted with more than two transmembrane domains at the same time. Although it is not definitive, the conclusion of Marullo et al. 13 is plausible because the role of antagonists is to prevent the receptor from becoming activated by binding to any domain of the receptor. In contrast with the antagonists, β 2 -adrenergic receptor subtype-selective agonists must activate the receptor by binding to a specific set of amino acids that are important for activation. There are several amino acids that are necessary for inducing the active conformation of the receptor following agonist binding.
Full agonists interact with several critical amino acids to maximally activate G-proteins. When a full agonist loses the interaction with some of the G-proteins, it becomes a partial agonist. Strader et al. reported that a Ser 204 or Ser 207 to Ala mutation resulted in receptors for which isoproterenol no longer behaves as a full agonist. 14 Isoproterenol becomes a partial agonist in these mutants. Strader et al. 14 have demonstrated that substitution of the catechol hydroxyl group with a hydrogen decreases the affinity of agonists for wild-type β 2 -adrenergic receptors and, thus, reduces their efficacy because the interaction important for full activation is lost following the Ala substitution.
AGONIST-SPECIFIC CHANGES IN RECEPTOR CONFORMATION
It has been reported that various β-adrenergic receptor agonists differentially couple with G s , G i and G q . 15 To explain this phenomenon, it has been postulated that β 2 -adrenergic receptors take on different conformations that are important for coupling with G-proteins. [15] [16] [17] Ghanouni et al. demonstrated that antagonist-, full agonist-and partial agonist-bound states are clearly different from each other. 18 Ghanouni et al. covalently attached a fluorophore to the G-protein-coupling domain of purified β 2 -adrenergic receptors and determined the fluorescence lifetime of the fluorophore. When a full agonist bound to the receptor, the G-protein-coupling domain showed two different conformations. Furthermore, the conformation induced by partial agonists is different from that induced by full agonists. This group also monitored agonist-induced conformational changes over time and demonstrated that agonists stabilize a succession of conformational states with distinct cellular functions. 19 However, the exact relationship between the nature of the agonist and the conformation linked to G-protein activation remains to be determined.
Basal cAMP production of constitutively active mutants increases as receptor expression levels increase. When various amino acids were introduced at the end of the intracellular third loop of α 1 -adrenergic receptors, the resulting mutants showed various degrees of constitutive activity. 20 This leads to speculation that receptors take on many conformations that determine the degree of interaction with G-proteins (Fig. 4) . The nature of the agonist determines the degree of coupling with G-proteins and it may determine the species of G-protein bound.
Many β-adrenergic receptor agonists stimulate not only G s , but also G q and G i to various degrees. 15, 17 G-Proteins are divided into four families: G s , G i , G q and G 12 . So far, it has not been determined whether β 2 -adrenergic receptors couple with the G 12 family of G-proteins (G 12 and G 13 ) in an agonist-specific manner. It would be interesting to determine the coupling of β 2 -adrenergic receptors with G 12 and G 13 , because the G 12 family of G-proteins mainly regulates the small G-protein Rho, which plays an important role in the contraction of smooth muscle, cytoskeletal rearrangement, cell movement and cell growth. 21 Smooth muscle is relaxed by stimulation of β 2 -adrenergic receptors. 22 Agonist stimulation of β 2 -adrenergic receptors may activate the Rho signaling pathway as well as the G s -cAMP pathway. When β 2 -adrenergic receptor stimulation relaxes smooth muscle, it may activate a contraction pathway through the G 12 -Rho pathway to avoid a maximally relaxed state.
Relationship between the β 2 -adrenergic receptor-selective biding site and the exosite of salmeterol Our group has reported previously that Tyr 308 in TM7 plays an important role in the high-affinity binding of β 2adrenergic receptor-selective agonists such as TA-2005, salmeterol, procaterol and formoterol. [7] [8] [9] When Tyr 308 was mutated to Ala, the resulting mutant had decreased affinity for all β 2 -adrenergic receptor-selective agonists. Because procaterol does not have a long substituted group at the amino group, contact with Tyr 308 in TM7 would seem difficult. However, the affinity for procaterol was decreased in Ala-substituted mutants of Tyr 308 , like for other β 2 -adrenergic receptor-selective agonists. The three-dimensional model of the β 2 -adrenergic receptor-ligand complex suggested that Tyr 308 locates above the substitute of the amino group and restricts the movement of the substituted group to the extracellular space from the upper side like a lid. 23 TA-2005 has a high affinity for β 2 -adrenergic receptors and a relatively long duration of action compared with salbutamol. However, the duration of action of TA-2005 is shorter than that of salmeterol. Salmeterol has a unique structure that is a long hydrophobic chain attached at the amino group. 24 The long hydrophobic chain is important not only for β 2 -adrenergic receptor selectivity, but also for the duration of action. The amino acid region that is necessary for the duration of action is different from that necessary for high-affinity binding. It is postulated that the long chain of salmeterol binds to a specific region of the receptor referred as the exosite, which allows it to persistently bind to the receptor. 24 Green et al. reported that lower half region of TM4 of the β 2 -adrenergic receptor is the site of the exosite. 25 They constructed various chimeric β 2 -and β 1 -adrenergic receptors and determined the region that is essential for the long duration of action of salmeterol. Because β 1 -adrenergic receptors do not bind salmeterol with high affinity and persistency, one of the chimeric receptors should reveal the critical region of the exosite. The chimeric approach also eliminates the possibility that the major exosite is a membrane lipid bilayer close to the receptor, because all chimeric receptors were expressed on the same cellular background. Green et al. 25 demonstrated that the chimeric receptor with TM4 of the β 1 -adrenergic receptor loses the long duration of action. Thus, they concluded that TM4 is a major candidate for the exosite. In contrast with the importance of TM7 for β 2 -adrenergic receptor selectivity, TM4 is important for the duration of action, but does not play any role in β 2 -adrenergic receptor-selective, high-affinity binding. In fact, the β 2 /β 1 chimeric receptor with the lower half region of TM4 of the β 1 -adrenergic receptor still retained its β 2 -adrenergic receptor selectivity for salmeterol comapred with wildtype β 2 -adrenergic receptor. 25 Rong et al. reported another candidate region for the exosite using a novel photoaffinity probe for salmeterol. 26 Its photoactivatable azide locates at the extreme end of the N-aryloxyalkyl chain of salmeterol, which confers the long duration of action of salmeterol. This probe labeled TM6 and TM7 of the β 2 -adrenergic receptor. Therefore, Tong et al. concluded that the exosite was located at TM6 and TM7 in addition to the lipid bilayer. 26 We have previously identified TM7 as the region that is essential for β 2 -adrenergic receptorselective, high-affinity binding. 7-9 Therefore, β 2 -adrenergic receptor selectivity and duration of action is governed by different regions of the receptor.
RESPONSES TO PARTIAL AGONISTS
Partial agonists cannot activate the receptor fully. However, partial agonists can induce cellular or tissue responses in similar extent to those induced by a full agonist. The receptor-mediated signaling is amplified at each step, as upstream signaling molecules produce an excess amount of messenger over the number of downstream signaling molecules. Thus, the final response is maximally induced by a small portion of upstream signaling molecules. Therefore, the dose-response curve of the final response will be shifted to the left compared with that obtained following binding of an agonist to the receptor. This is the reason that weak activation of receptors by partial agonists can still induce maximal responses in cells or tissues.
Signaling by β 2 -adrenergic receptor stimulation is almost exclusively through adenylyl cyclase and protein kinase A (PKA) activation. However, it has been reported that stimulation of β 2 -adrenergic receptors induces several responses via activated G s but not adenylyl cyclase and PKA activation. 27 For instance, calcium channels, c-Src tyrosine kinase and RGS-PX1 (one of the sorting nexins) have been reported to interact with and be activated by G s . 27 The effects of partial agonists on these effectors have not been determined in detail yet. It is interesting to examine the effects of partial agonists on effectors other than adenylyl cyclases, because they may elicit physiological responses via a cAMP (adenylyl cyclase)-independent pathway.
DESENSITIZATION AND PARTIAL AGONISTS
What is a clinical benefit of partial agonists? Partial agonists are believed to induce less desensitization than full agonists. 28 Desensitization is defined as a reduced response upon second stimulation. 29 When the second stimulant is the same as the first stimulant, the phenomenon is referred as homologous desensitization. When the second stimulant is different from the first stimulant and still shows a reduced response, it is referred as heterologous desensitization. Desensitization consists of three processes: uncoupling, internalization and downregulation. Uncoupling occurs in seconds. Internalization occurs in minutes and downregulation occurs in hours to days (Fig. 5) . The most important factor for desensitization is downregulation at the whole-body level becase an agonist is administered for long periods of time to treat disease. The number of receptors is kept low (typically fmol/mg protein) in native cells and agonist-induced responses are positively correlated with the number of receptors. When receptor expression levels are decreased by agonist stimulation, there is a direct link with the decreased response. Because agonists are frequently used for the treatment of disease, it is necessary to elucidate the mechanism of downregulation. Furthermore, elucidation of the mechanism of agonist-induced downregulation may lead to the discovery of a novel therapeutic target for drug research. A detailed mechanism for downregulation has not been established so far. However, it is believed that a part of the downregulation process is possibly mediated by a second messenger-dependent pathway. Because agonist efficacy correlates with the production of second messengers, such as cAMP and Ca 2+ , it is beneficial to use partial agonists to avoid downregulation.
There are several mechanisms through which receptors can be downregulated: (i) increased degradation of receptor protein; (ii) decreased transcription of receptor mRNA; (iii) decreased synthesis of receptor protein; and (iv) decreased stability of receptor mRNA. Second messengers are involved, at least, in the decreased stability of mRNA. 30 The degree of contribution of the other mechanisms to downregulation is not known. Partial agonists do not increase second messengers to the same extent as full agonists. Thus, treatment with partial agonists induces less downregulation than that induced following treatment with a full agonist. Accelerated degradation of receptor protein is partially mediated by internalization and then targeting to the lysosome. 29, 31 Although the mechanism of targeting to the lysosome is unknown, the internalization process that partially links to lysosome targeting is dependent on the strength of agonist stimulation. Therefore, partial agonists have an advantage over full agonists because they induce a lesser degree of downregulation through the lysosome.
INTERNALIZATION, LYSOSOME TARGETING AND DESENSITIZATION
Internalization of the GPCR has been studied extensively for β 2 -adrenergic receptors and a basic mechanism of internalization is emerging. 31 Agonist stimulation leads to phosphorylation of the receptor by G-protein-coupled receptor kinase (GRK). The GRK only phosphorylates receptors in an active conformation. The degree of GRK-mediated phosphorylation following agonist stimulation is correlated with the efficacy of an agonist. 32 Receptors phosphorylated by GRK, but not second messenger-dependent protein kinases, such as PKA, are targeted by β-arrestin. β-Arrestin is a cytosolic protein that translocates to the membrane following agonist stimulation. Coupling with the G-protein is then inhibited by receptor-bound β-asrrestin. The GRK also have a regulator of G-protein signaling (RGS) domain that binds to G-proteins and accelerate GTPase activity. 33 Therefore, GRK participates in uncoupling by two mechanisms: (i) the inhibition of coupling by phosphorylation; and (ii) the increased turn-off reaction by the RGS domain. β-Arrestin binds clathrin and adaptin, the interaction of which is essential for agonist-stimulated internalization through clathrin-coated pits. 29, 31 After β 2 -adrenergic receptors are internalized, a part of the receptor is targeted to the lysosome. 29, 31 Although it is not known what signal targets the receptor to the lysosome, the carboxyl terminal PDZ domain of the β 2 -adrenergic receptor has been proposed to be main determinant of lysosome targeting. 34 The phosphorylation of amino acids in the PDZ domain switches the receptor from a recycling process to lysosome targeting. This phosphorylation of the PDZ domain has been reported to be mediated by GRK5. 34 The GRK5-mediated phosphorylation results in the release of Na + /H + exchanger regulatory factor (NHERF), which binds this carboxyl terminal PDZ domain. Then, the phosphorylated receptor is targeted to the lysosome.
β-Arrestin works as an adaptor protein linking β 2adrenergic receptors to internalization. However, a β-arrestin-independent internalization pathway also exists, which is believed to depend on the type of receptor. 31 Fig. 5 Schema of the internalization, recycling and degradation of receptors. Agonist stimulation leads to G-proteincoupled receptor kinase-mediated phosphorylation and the phosphorylated receptor recruits β-arrestin to the membrane. The receptor-β-arrestin complex is trafficked to the endosome and recycled back after dephosphorylation. Some of the internalized receptors are targeted to the lysosome for degradation. The processes of internalization, translocation to the endosome and recycling occurs rapidly or slowly, depending on the type of receptor.
Ubiquitination is a signal of protein degradation. Shenoy et al. reported that β 2 -adrenergic receptors and β-arrestin are ubiquitinated when the receptors were stimulated by the agonist isoproterenol. 35 Two hybrid assays revealed that β-arrestin interacts with one of the ubiquitin ligases (Mdm2) and that this interaction is essential for ubiquitination of β-arrestin. The Mdm2mediated ubiquitination of β-arrestin is required for receptor-mediated internalization. However, ubiquitination of β 2 -adrenergic receptors is mediated by an unidentified ubiquitin ligase and the role of receptor ubiquitination has not been determined.
It is generally believed that receptor internalization does not contribute to desensitization. 29 Instead, internalization is proposed to be a process of resensitization through dephosphorylation by internalized vesicleassociated phosphatase. 31, 36 However, the mechanism of desensitization has been examined in artificially overexpressing cells in almost all cases. The level of expression in native cells or tissues is relatively low compared with overexpressing cells. Because the receptor-mediated response positively relates with the number of receptors expressed on the cell surface, internalization may contribute to the uncoupling of the receptor from G-proteins under the physiological circumstances.
Receptor phosphorylation is not enough for tight binding of β-arrestin to the phosphorylated receptor. 31 The tight binding of β-arrestin to the phosphorylated receptor requires the presence of an agonist. Therefore, the agonist-bound and phosphorylated receptor binds β-arrestin tightly and, consequently, is uncoupled from G-proteins. Partial agonists cause less desensitization than full agonists, because partial agonist-induced phosphorylation by GRK and the subsequent binding of β-arrestin is weaker than for full agonists. 28 The structural determinant of rapid recycling or lysosome trafficking exists in the receptor sequence itself, because two different receptors expressed in the same cell show different behaviors of recycling and degradation. However, it is more complex than thought, because opiate receptor trafficking to the lysosome is dependent on the type of agonist. [37] [38] [39] Trafficking of β 2 -adrenergic receptors to the lysosome may also be dependent on the agonist and partial and full agonists can differentially regulate lysosome trafficking.
CENTRAL ROLE OF β-ARRESTIN IN RECEPTOR

REGULATION AND SIGNALING
β-Arrestin is a cytosolic protein that binds to the phosphorylated and activated form of the receptor. 29, 31 The binding of β-arrestin uncouples the receptor from G-proteins. However, the binding of β-arrestin to the phosphorylated receptor also produces new signaling. It mediates mitogen-activated protein kinase activation, such as extracellular signal-regulated kinase (ERK) 1/2 and c-Jun NH 2 -terminal kinase (JNK) 3 by interacting Fig. 6 Polymorphism of human β 2 -adrenergic receptors. It has been reported that amino acids Arg, Gln, Met or Thr at position 16, 27, 34 or 164 are changed to Gly, Glu, Val or Ile, respectively. 40 In addition to these polymorphisms, there is a polymorphism at the 5′ leader cistron (-47 nucleotide) encoding the 19 amino acid peptide referred as the β 2 -adrenergic receptor upstream peptide (BUP), which controls translation of the β 2 -adrenergic receptor. The amino acid Arg 19 in the BUP is changed to Cys by this polymorphism. Two polymorphisms are presented in the figure. The change of Arg 16 in the coding region to Gly is proposed to be linked with the albuterol response. 42, 43 (Refer to the text for details.) with various regulatory proteins, such as JNK, apoptosisstimulating kinase and Src. 30 Thus, β-arrestin has been proposed to be a scaffold protein that assembles signaling molecules to efficiently transduce the signal downstream (Table 1) . Unfortunately, the differential effects of agonists, including full and partial agonists, have not yet been determined.
POLYMORPHISM OF β 2 -ADRENERGIC RECEPTORS AND AGONIST ACTIONS
Polymorphism is defined as the genetic variation observed in more than 1% of the population. It has been reported for human β 2 -adrenergic receptors that Arg, Gln, Met and Thr at positions 16, 27, 34 and 167 are changed to Gly, Glu, Val and Ile, respectively ( Fig. 6 ). 40 Green et al. reported the relationship between polymorphism of Arg 16 and agonist-induced regulation. 41 They expressed the Gly-or Glu-substituted mutants and compared the pharmacological and biochemical characteristics of these mutants, such as binding and desensitization, with those of the wild-type receptor. Green et al. 41 found that substitution of Arg at position 16 with Gly results in a receptor that shows slightly, but significantly, enhanced downregulation following prolonged stimulation with isoproterenol. The clinical significance of substitution of Arg to Gly has been reported by two groups. Martinez et al. have found that homozygotes and heterozygotes for Arg 16 were 5.3-and 2.3fold, respectively, more likely to respond to albuterol. 42 Albuterol is a partial agonist and is used in the treatment of asthma. The responses to albuterol were correlated with genetic variation at Arg 16 . Israel et al. have reported that the homozygous Arg 16 /Arg 16 patient shows clear tachyphylaxis, although patients within the entire population did not show tachyphylaxis following regular use of albuterol. 43 Further investigations will help to treat patients based on their genetic background. CONCLUSIONS β 2 -Adrenergic receptors have been analyzed in detail in terms of their structure and functional regulation. It has been shown that agonist binding to the receptor induces ligand-specific conformational changes and subsequent signaling through G-proteins. Partial agonists can be differentiated from full agonists by the ability to activate Gproteins and partial agonists produce less desensitization. Almost all research has been performed with full agonists and the detailed analysis of the regulation and signaling induced by partial agonists has not been determined. Because partial agonists are used for clinical purposes, it is necessary to examine the signaling, regulation and binding of β 2 -adrenergic receptors induced by partial agonist.
